Immunovant (IMVT) reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study in CIDP. The Phase 3 study in MG is a randomized ...

Batoclimab met the primary endpoint in a Phase 3 MG study, showing up to a 5.6-point MG-ADL improvement with 74% mean IgG reduction. Immunovant will not seek approval for batoclimab in MG or CIDP ...

Safety and tolerability were observed to be consistent with prior batoclimab studies. Path Forward in MG and CIDP Immunovant plans to initiate potentially registrational studies in both MG and ...

On the flip side, Immunovant noted that for the time being it would not seek regulatory filings for batoclimab. Why is that? Well, that's because as I noted above in the beginning, it is awaiting ...

But Roivant Sciences and Immunovant don't expect to seek approval for batoclimab in myasthenia gravis or CIDP. The companies believe IMVT-1402 will lead to better reductions in IgG levels.

patients were randomized into 680mg and 340mg batoclimab only, the firm says. The firm has a Buy rating and $51 price target on Immunovant shares, and says the “more is better” debate has not ...

Immunovant does not intend to seek regulatory approval for batoclimab in MG or CIDP and is focused on leveraging data and learnings from the batoclimab studies to accelerate programs with IMVT-1402.

Safety and tolerability were observed to be consistent with prior batoclimab studies. Immunovant plans to initiate potentially registrational studies in both MG and CIDP with lead asset IMVT-1402 and ...